Domatinostat in Combination With Avelumab in Patients With Treatment-naïve Metastatic Merkel Cell Carcinoma (MERKLIN 1)

NCT04874831 | Withdrawn Phase 2 DMC FDA Drug

• 2 other identifiers: 4SC-202-4-20192019-003575-19
• Study Type: interventional
• Target: N/A
• Locations: 0 countries
• Sites: N/A

Brief Summary

This phase II trial studies how well domatinostat (4SC-202) works in combination with avelumab in adult patients with treatment-naïve metastatic Merkel Cell Carcinoma

Conditions

Merkel Cell Carcinoma

Outcome Measures

Primary Outcomes (1)

• Confirmed Objective Response (OR)

  Confirmed Objective Response (OR) according to RECIST vl.l, determined by independent review. Both Complete Response and Partial Response must be confirmed by a second tumor assessment preferably at the regularly scheduled 6-weeks assessment interval, but no sooner than 4 weeks after the initial diagnosis of CR or PR.

  up to 1 year

Secondary Outcomes (12)

• Duration of Response (DOR)

  up to 1 year

• Durable Response (DR)

  up to 1 year

• Overall Survival (OS)

  approx 3.5 years

• Progression Free Survival (PFS)

  approx. 3 years

• Disease Control (DC)

  up to 1 year

Study Arms (1)

domatinostat and avelumab

EXPERIMENTAL

Single arm study of Domatinostat tablets in combination with avelumab infusion

Drug: domatinostat in combination with avelumab

Interventions

domatinostat in combination with avelumab DRUG

domatinostat tablets and avelumab infusion

domatinostat and avelumab

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Signed written informed consent.
• Age 18 years at signature of Informed Consent Form (ICF).
• Histologically proven MCC.
• Confirmation of the diagnosis by immune-histochemistry as per standard at the institution, including (but not limited to) CK20 and TTF-1.
• Patients must have metastatic or distally recurrent disease; Ml status must be confirmed at entry.
• Patients must not have received any prior systemic treatment for metastatic MCC. Prior treatment in the adjuvant setting (no clinically detectable disease; no metastatic disease) will be allowed, if the end of the treatment occurred at least 6 months prior to study entry, i.e. signing ICF.
• Fresh biopsy or archival tumor tissue (not older than 3 months) from an unirradiated lesion.
• Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 1 at study entry.
• Estimated life expectancy of more than 12 weeks.
• Disease must be measurable with at least one unidimensional measurable lesion by RECIST vl.l (including skin lesions).
• Adequate hematological and organ function defined by the following parameters:
• Adequate hematological function defined by
• White blood cell count (WBC) \> 3000/pl
• Absolute Neutrophil Count (ANC) \> 1500/pl
• Lymphocyte count \> 500/pl

You may not qualify if:

• Participation in another interventional clinical study within the past 30 days (participation in observational studies is permitted)
• Concurrent treatment with a non-permitted drug.
• Prior therapy with any histone deacetylase (HDAC) inhibitor or antibody/drug targeting T cell coregulatory proteins (immune checkpoints) such as anti-programmed death 1 (PD-1), antiprogrammed death-ligand 1 (PD-L1) or anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4) antibody.
• Concurrent anti-cancer treatment (for example, cytoreductive therapy, radiotherapy, immune therapy, or cytokine therapy except for erythropoietin). Radiotherapy administered to superficial lesions is not allowed if such lesions are considered target lesions in the efficacy evaluation or may influence the efficacy evaluation of the study treatment.
• Major surgery for any reason, except diagnostic biopsy, within 4 weeks and/or if the subject has not fully recovered from surgery.
• Concurrent systemic therapy with steroids or other immunosuppressive agents (e.g. methotrexate, azathioprine, interferons, mycophenolate, anti-TNF agents and other), or the use of any investigational drug within 28 days before the start of study treatment. Short-term administration of systemic steroids e.g. for allergic reactions or the management of immune-related adverse events \[irAE\] while on study is allowed. Also, patients requiring hormone replacement with corticosteroids for adrenal insufficiency are eligible if the steroids are administered only for purpose of hormonal replacement and at doses \< 10 mg or equivalent prednisone per day.
• Conditions requiring systemic anti-arrhythmic therapy known to prolong QT/QTc interval, patients with QTcF interval \>480 msec on at least 2 separate and consecutive ECGs at screening or a medical history of long-QT-Syndrome.
• Patients with active central nervous system (CNS) metastases are excluded and a brain CT/MRI will be required during screening if not performed within 6 weeks prior to the planned start of the study treatment. Subjects with a history of treated CNS metastases (by surgery or radiation therapy) are not eligible unless they have fully recovered from treatment, demonstrated no progression for at least 2 months, and do not require continued steroid therapy.
• History of or concurrent malignancies, except the malignancy is clinically insignificant, no systemic treatment is or has been required for the last 6 months, and the patient is clinically stable
• Prior organ transplantation (including allogeneic stem-cell transplantation).
• Any active gastrointestinal disorder that could interfere with the absorption of domatinostat characterized by malabsorption or inability to swallow tablets as per judgment of the Investigator.
• Positive testing for HIV or known AIDS or HBV or HCV infection at screening (positive HBV surface antigen or HCV RNA if anti-HCV antibody screening is positive).
• Active or history of any autoimmune disease (except for patients with vitiligo) or immune-diseases that required treatment with systemic immune modulating drugs.
• History or current evidence of clinically relevant allergies or hypersensitivity, which includes known or suspected intolerabilities attributed to domatinostat or avelumab or to constituents of the domatinostat tablets or avelumab infusion and known severe hypersensitivity reactions (Grade 3) to monoclonal antibodies.
• Persisting toxicity related to prior therapy Grade \> 1 National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0; however, sensory neuropathy Grade \< 2 will be acceptable.

Sponsors & Collaborators

• 4SC AG: lead
• Merck KGaA, Darmstadt, Germany: collaborator

MeSH Terms

Conditions

Carcinoma, Merkel Cell

Interventions

domatinostat; avelumab

Condition Hierarchy (Ancestors)

Polyomavirus Infections; DNA Virus Infections; Virus Diseases; Infections; Tumor Virus Infections; Carcinoma, Neuroendocrine; Neuroendocrine Tumors; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms; Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms, Nerve Tissue

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 15, 2021
• First Posted: May 6, 2021
• Study Start: November 1, 2021
• Primary Completion: September 1, 2025
• Study Completion: September 1, 2025
• Last Updated: November 18, 2021

Record last verified: 2021-11

Data Sharing

• IPD Sharing: Will not share